Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
AI Generated Analysis | Feedback
Here are 1-3 brief analogies for Insulet (PODD):
Like Medtronic, but specializing in user-friendly, tubeless insulin pumps.
The Apple of insulin pumps, known for its discreet, wearable, and user-friendly patch designs.
Like Dexcom, but for automated insulin delivery via a tubeless patch pump instead of glucose monitoring.
AI Generated Analysis | Feedback
- Omnipod DASH Insulin Management System: A tubeless, wearable insulin pump controlled by a smartphone-like Personal Diabetes Manager (PDM) to deliver insulin continuously.
- Omnipod 5 Automated Insulin Delivery System: An advanced hybrid closed-loop insulin delivery system that integrates with continuous glucose monitors (CGMs) to automatically adjust insulin delivery based on glucose readings.
AI Generated Analysis | Feedback
Insulet (PODD) primarily sells its Omnipod Insulin Management System directly to individuals with diabetes. While the fulfillment and reimbursement process involves healthcare providers, pharmacies, and third-party payers, Insulet's direct marketing and sales efforts are aimed at the end-users.
The company serves the following categories of customers:
- Individuals with Type 1 Diabetes: This represents the largest segment of insulin pump users, as these individuals require lifelong insulin therapy and benefit significantly from continuous insulin delivery systems like Omnipod for better glucose management.
- Individuals with Type 2 Diabetes: A growing number of individuals with Type 2 diabetes who require intensive insulin therapy (e.g., multiple daily injections) are adopting insulin pump technology to help manage their condition more effectively.
- Parents/Guardians of Pediatric Patients with Diabetes: For children and adolescents living with diabetes, parents or guardians are the primary decision-makers and managers of their child's diabetes care, including the selection and use of insulin delivery devices like the Omnipod system.
AI Generated Analysis | Feedback
- Flex Ltd. (FLEX)
- Sanmina Corporation (SANM)
AI Generated Analysis | Feedback
Ashley McEvoy, President and Chief Executive Officer
Ms. McEvoy has served as Insulet's President and Chief Executive Officer since April 2025. She previously spent nearly three decades in leadership roles of increasing responsibility at Johnson & Johnson (J&J), concluding her tenure in 2023 as Executive Vice President and Worldwide Chairman of J&J's MedTech business, an organization with 60,000 global employees and over $30 billion in revenue. During her five-year tenure leading MedTech, Ms. McEvoy spearheaded a significant turnaround, tripling revenue growth. Her prior roles at J&J included Company Group Chairman of Consumer Medical Devices, Group Chairman of Vision and Diabetes Care, Worldwide President of Ethicon Products, and President of McNeil Consumer Healthcare. Ms. McEvoy also serves on the Board of Directors of Procter & Gamble.
Flavia Pease, Executive Vice President, Chief Financial Officer
Ms. Pease became Insulet's Executive Vice President, Chief Financial Officer, effective September 30, 2025. Prior to joining Insulet, she served as Corporate Executive Vice President and Chief Financial Officer at Charles River Laboratories from 2022. Before that, Ms. Pease spent 23 years at Johnson & Johnson, holding various senior finance and leadership positions across the Medical Devices and Pharmaceutical segments. Her roles at J&J included Vice President and Group Chief Financial Officer of the global Medical Devices business, where she oversaw financial operations for a $27 billion global portfolio, and Vice President of Finance for Janssen North America. She began her career in investment banking in Brazil and also held positions at SC Johnson. Ms. Pease also served on Insulet's Board of Directors from January 2024 until her appointment as CFO.
Eric Benjamin, Executive Vice President, Chief Operating Officer
Mr. Benjamin was appointed Executive Vice President, Chief Operating Officer in August 2025. He leads the company's growth and innovation engine, overseeing Strategy & Business Development, the Office of the Chief Technology Officer, Research & Development, and the newly created Growth organization. Since joining Insulet in 2015, Mr. Benjamin has been instrumental in transforming the company into a digital-native platform business, launching Omnipod DASH® and Omnipod 5®, strengthening the supply chain, and expanding into the type 2 diabetes market. Before Insulet, he held senior roles in R&D, quality, and operations at Abbott in the U.S. and Europe.
John Kapples, Senior Vice President and General Counsel
Mr. Kapples has served as Insulet's Senior Vice President and General Counsel since March 2019. From 2015 to 2019, he was Vice President, Secretary, and General Counsel at GCP Applied Technologies, Inc. Prior to that, Mr. Kapples served as Vice President and Corporate Secretary of Covidien plc from 2006 to 2015, which was acquired by Medtronic plc in 2015. At Covidien, he was responsible for building the company's legal structure and compliance framework and advising on strategic transactions. His career also includes roles at Raytheon Company and Sullivan & Worcester LLP.
Manoj Raghunandanan, Chief Growth Officer
Mr. Raghunandanan was appointed Chief Growth Officer in August 2025. He brings over 20 years of global consumer health leadership experience, primarily from Kenvue (formerly Johnson & Johnson Consumer Health). Most recently, he was the general manager of Kenvue's Northern European business and previously served on its Executive Committee for five years, overseeing a $6 billion global over-the-counter portfolio. Mr. Raghunandanan has held senior leadership roles across the U.S., Europe, and Asia, focusing on building high-performing teams, driving commercial excellence, and scaling global brands.
AI Generated Analysis | Feedback
Beta Bionics' iLet Bionic Pancreas system, which recently received FDA clearance and is beginning its commercial rollout, represents a clear emerging threat. The iLet system features a unique algorithm that significantly simplifies automated insulin delivery by largely eliminating the need for carb counting, requiring only meal announcements from the user. This highly simplified user experience could redefine patient expectations for ease of use in insulin pumps and challenge Insulet's market position by offering a compelling alternative to current automated insulin delivery systems like the Omnipod 5, despite the iLet system being tubed.
AI Generated Analysis | Feedback
The addressable markets for Insulet's main products and services, primarily its Omnipod insulin delivery system, are as follows:
- Insulet estimates its total addressable market for insulin-intensive diabetes (Type 1 and insulin-intensive Type 2) to be approximately 14 million people globally.
- In the U.S., the addressable market for insulin-requiring type 2 diabetes is approximately 6 million people. This includes 2.5 million individuals on insulin-intensive multiple daily injections (MDI) and over 3 million on basal-only therapy.
For the broader insulin pump market, which includes Insulet's offerings:
- The global insulin pump market was valued at approximately $5.6 billion in 2024 and is projected to reach approximately $8.8 billion by 2033, growing at a compound annual growth rate (CAGR) of 5.1% from 2025 to 2033. Other estimates indicate the global insulin pump market size was approximately $5.90 billion in 2024 and is expected to reach $9.66 billion by 2030, with a CAGR of 8.42% from 2025 to 2030. In 2025, the global insulin pump market is estimated to be around $6.25 billion.
- North America holds a significant share of the global insulin pump market, accounting for over 37% of the global revenue in 2025, with a market size of approximately $2.31 billion. In 2024, North America held the largest market share at 45.53%.
AI Generated Analysis | Feedback
Insulet (PODD) is poised for future revenue growth over the next two to three years, driven by several key strategic initiatives and market expansions:
-
Expansion into the Type 2 Diabetes Market: Insulet received FDA clearance for its Omnipod 5 system for adults with Type 2 diabetes, significantly expanding its total addressable market. This move allows Insulet to target a much larger patient population, with approximately 6 million people in the U.S. living with insulin-requiring Type 2 diabetes. The company views this as a significant growth opportunity.
-
Accelerated International Growth of Omnipod 5: Insulet is focused on driving international expansion with new launches of Omnipod 5 planned in additional countries starting in early 2025. The company has seen robust demand for Omnipod 5 internationally, with international sales growing significantly in recent quarters. This continued global rollout is expected to be a substantial revenue driver.
-
New Product Integrations and Enhancements (Omnipod 5 platform advancement): Ongoing product innovation and integration efforts are expected to contribute to revenue growth. Recent milestones include the launch of Omnipod 5 with Dexcom's G7 continuous glucose monitoring (CGM) sensor in several European countries and the U.S., with plans to introduce Omnipod 5 integrated with Abbott's FreeStyle Libre 2 Plus sensor. These integrations enhance the system's capabilities, improve user experience, and expand customer choice.
-
Increased Customer Acquisition and Retention: Insulet anticipates continued year-over-year growth in new customer starts in both the U.S. and internationally. This growth is driven by the appeal of the Omnipod 5 platform and increased penetration among users of multiple daily injections (MDI). Efforts to enhance customer experience and expand commercial reach also support this driver.
-
Positive Price/Mix Realization: Particularly in international markets, Insulet expects a benefit from positive price/mix realization as customers transition from the Omnipod DASH system to the advanced Omnipod 5. This shift to the newer, more sophisticated product positively impacts average selling prices and revenue per user.
AI Generated Analysis | Feedback
Share Repurchases
- In March 2025, Insulet's Board of Directors authorized a program to repurchase up to $125 million of common stock through December 31, 2026, intended to offset dilution from stock-based compensation.
- During the nine months ended September 30, 2025, the company repurchased approximately 184 thousand shares for $59.6 million under this program.
- In the second quarter of 2025, Insulet repurchased 93,000 shares for approximately $30 million.
Share Issuance
- For the nine months ended September 30, 2025, Insulet recorded $17.2 million from the exercise of options to purchase common stock.
- The issuance of shares for the employee stock purchase plan contributed $7.1 million for the nine months ended September 30, 2025.
- Stock-based compensation expense totaled $42.4 million for the nine months ended September 30, 2025.
Capital Expenditures
- Capital expenditures were $56.5 million for the nine months ended September 30, 2025, a decrease from $71.3 million for the same period in 2024.
- The decrease in capital expenditures for the nine months ended September 30, 2025, was primarily due to the prior year's significant purchases of machinery, equipment, and tooling for the Malaysia manufacturing facility.
- Capital expenditures are expected to be slightly higher in 2025 compared to the prior year, focusing on supporting manufacturing and global expansion.
